Warning-
as we can see that the pharma sector is showing steady strength and Lupin Limited has been maintaining strong momentum backed by robust earnings growth, where recent quarters showed solid revenue expansion and sharp profit jump driven by strong US sales and improving margins
technically, stock is trading near its higher range and sustaining above key support zones, indicating accumulation and potential breakout continuation
Disclaimer– Registration granted by SEBI, membership of a SEBI recognized supervisory body (BSE) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Disclosure– Investments in securities market are subject to market risks, read all the related documents carefully before investing.